The goal of this study is to preliminarily determine/estimate feasibility and whether frequent and early conivaptan use, at a dose currently determined to be safe (i.e., 40mg/day), is safe and well-tolerated in patients with cerebral edema from intracerebral hemorrhage (ICH) and pressure (ICP). A further goal is to preliminarily estimate whether conivaptan at this same dose can reduce cerebral edema (CE) in these same patients. This study is also an essential first step in understanding the role of conivaptan in CE management.
Hypothesis: The frequent and early use of conivaptan at 40mg/day will be safe and well-tolerated, and also reduce cerebral edema, in patients with intracerebral hemorrhage and pressure.

开始日期2017-03-22

申办/合作机构

Allina Health System, Inc.

NCT01954290

/ Withdrawn临床2期IIT

Treatment of Brain Edema and Herniation Secondary to Ischemic or Hemorrhagic Stroke

Stroke remains the fourth leading cause of death in the United States (second worldwide) and a leading cause of long-term disability, resulting in total direct and indirect costs of approximately $73.7 billion annually. The failure of novel therapies in clinical trials demonstrates that the complex neural response to stroke must be targeted at multiple levels to improve patient outcomes. Despite significant improvements in stroke treatment and management, 1 year survival rate among stroke patients aged 65 years or more is around 25%, and 5- year survival rate amounts to approximately 50%. The highest chances of death are within 30 days of stroke. Mortality increases due to worsening brain dysfunction, elevated intracranial pressure (ICP), and other comorbid conditions.
Treatments aimed at reducing post-stroke cytotoxic edema may reduce the risk for development of malignant stroke and mortality. Current treatments such as osmo-therapy and hemicraniectomy have substantial limitations, and mortality remains high, despite these measures outcomes remain unsatisfactory. There is a great need for alternative medical approaches which are safe, predictable, and help to ameliorate post stroke edema.

开始日期2015-09-01

申办/合作机构

University of Florida

NCT01752543

/ Completed临床4期IIT

Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients

The purpose of the present study is to evaluate the effects of a blockade of the vasopressin system and central hemodynamic system in heart failure (HF) patients during physical exercise. The significance of the vasopressin system during physical exercise is unclear. If vasopressin is a significant regulator of exercise hemodynamics in HF, strategies to intervene against activation of the V1A-receptor might be expected to improve HF symptoms and possibly outcome.
The potential effects of the central hemodynamic system will be evaluated with a Swan-Ganz catheter. Echocardiography will be performed at rest and during submaximal working capacity before and during the infusion of a vasopressin receptor antagonist (conivaptan) or placebo. Cardiac output will be measured by thermodilution. The exercise test will be performed at 50 % of VO2 max and hemodynamic and echocardiographic measurements will be collected. The exercise test will be performed on a supine multistage bicycle.

开始日期2013-12-01

申办/合作机构

Rigshospitalet

[+1]

100 项与盐酸考尼伐坦相关的临床结果

登录后查看更多信息

100 项与盐酸考尼伐坦相关的转化医学

登录后查看更多信息

100 项与盐酸考尼伐坦相关的专利（医药）

登录后查看更多信息

320

项与盐酸考尼伐坦相关的文献（医药）

2026-01-02·JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

Computational approach towards repurposing of FDA approved drug molecules: strategy to combat antibiotic resistance conferred by Pseudomonas aeruginosa

Article

作者: Chatterjee, Debolina ; Sivashanmugam, Karthikeyan

Antimicrobial resistance is recognized as a major worldwide public health dilemma in the current century. Pseudomonas aeruginosa, a Gram-negative opportunistic pathogen, causes nosocomial infections like respiratory tract infections, urinary tract infections, dermatitis, and cystic fibrosis. It manifests antibiotic resistance via intrinsic, acquired, and adaptive pathways, where efflux pumps function in the extrusion of antibiotics from the cell. MexB protein, part of the tripartite efflux pumps MexAB-OprM present in P.aeruginosa, expels the penems and β-lactam antibiotics, thereby enhancing Pseudomonas resistance. The current study was intended to screen around 1602 clinically approved drugs to understand their ability to inhibit the MexB protein. Amongst them, the top 5 drug molecules were selected based on the binding energies for analyzing their physio-chemical and toxicity properties. Lomitapide was found to have the maximum negative binding energy followed by Nilotinib, whereas Nilotinib's number of hydrogen bonds was higher than that of Lomitapide. ADMET study revealed that all 5 drug molecules had limited solubility. Also, Lomitapide and Venetoclax showed low bioavailability scores, while Nilotinib, Eltrombopag, and Conivaptan demonstrated higher potential for therapeutic levels. A molecular dynamic simulation study of the 5 drugs against MexB was carried out for 200 nanoseconds. The RMSD, RMSF, Hydrogen bond formation, Radius of gyration, SASA, PCA, DCCM, DSSP and MM-PBSA binding energy calculation along with demonstrated high stability of the MexB-Nilotinib complex with lesser distortions. Our study concludes, that Nilotinib is a potential inhibitor and can be developed as a therapeutic agent against MexB protein for controlling P. aeruginosa infections.

2025-12-01·JOURNAL OF ALZHEIMERS DISEASE

Virtual screening of drugs against multiple targets of Alzheimer's disease

Article

作者: Mesfin, Samuel ; Bloch, Naamah ; Ben Zaken, Karin ; Samson, Abraham O

Background:

Drug repurposing offers a rapid, cost-effective approach for discovering therapies against multiple targets.

Objective:

Here, we screen virtual ligand libraries consisting of 3468 approved drugs against 11 protein targets associated with Alzheimer's disease (AD).

Methods:

We employ blind molecular docking, and target amyloid-β (Aβ), microtubule-associated protein tau (MAPT), Apolipoprotein E4 (APOE4), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), amyloid-β protein precursor (AβPP), β-secretase (BACE1), brain-derived neurotrophic factor (BDNF), presenilin 1 (PSEN1) and 2 (PSEN2), and α-synuclein (SNCA) proteins using AutoDock Vina.

Results:

Notably, multitarget binding recurs among the top-10 ligands with Ergotamine and Dihydroergotamine potentially binding 8; Dutasteride 7; Drospirenone and Nilotinib 6; Adapalene and Conivaptan 5; Bromocriptine 4; and Rolapitant, Irinotecan, Plerixafor, Saquinavir, and Telmisartan 3, out of 11 protein targets. As such, we reveal potential binding sites for ergot alkaloids, steroids, retinoids, antivirals, angiotensin receptor blockers, and Neurokinin 1 (NK1) receptor antagonists on multiple AD targets. Importantly, the therapeutic potential of the top-scoring ligands is confounded by pharmacokinetics and adverse-effects. For example, poor blood-brain barrier (BBB) penetration, and vasoconstriction, discount ergot-alkaloid use in AD. Likewise, potential toxicity limits prolonged use of steroids, Nilotinib, Adapalene, and Irinotecan. Conversely, BBB penetration, neuronal protection, oral availability, anti-inflammation, and anti-hypertension, admit Angiotensin receptor blockers (ARB), (Telmisartan/Candesartan); Antidiuretic hormone (ADH) inhibitors (Conivaptan/Tolvaptan); and of the NK1 receptors antagonists (Rolapitant/Netupitant) use in AD.

Conclusions:

Our multitarget screening identifies selective synergistic AD modulators, such as ARB, ADH and NK1 receptor inhibitors, and simplifies drug discovery by focusing on the most promising candidates for experimental validation.

2025-11-07·JOURNAL OF ORGANIC CHEMISTRY

Article

作者: Zhang, Fangjun ; Jiang, Rong ; Zheng, Wenjie ; Yang, Jianing ; Hu, Yuanling ; Xu, Moke ; Shao, Yinlin ; Chen, Wenwen ; Jin, Qian

This investigation presents an innovative methodology for the direct deoxygenative alkenylation of ketones, utilizing pinacolborane as the reducing agent in the presence of the B(C₆F₅)₃ catalyst. A series of aryl ketones containing different functional groups such as hydroxyl, amino, alkynyl, vinyl, and ester groups were found to be well-tolerated. The efficiency of deoxygenative alkenylation could be notably improved by the addition of catalytic LuCl₃ in some substrates. This transformation has also been nicely applied to the gram-scale late-stage functionalization of pharmacologically significant compounds sertraline and conivaptan. Comprehensive mechanistic investigations have elucidated a plausible reaction pathway that proceeds through sequential carbonyl hydroboration, deboration, and deprotonation processes.

项与盐酸考尼伐坦相关的新闻（医药）

2026-02-25

·PRNewswire

CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®

NASHVILLE, Tenn., Feb. 25, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, today announced the launch of its national sales promotional for Talicia ®. Cumberland has assumed responsibility for the distribution and sales promotion of the brand in the U.S. under the co-commercialization agreement with RedHill Biopharma. Talicia is an FDA-approved oral capsule indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer. Talicia is the only all-in-one treatment containing omeprazole, amoxicillin and rifabutin and is now listed as a first-line option in the American College of Gastroenterology guidelines for H. pylori infections. Talicia is patent protected through 2042 and received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product designation. "We believe this represents an important catalyst for the next phase of Talicia's growth," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. "We are executing the full breadth of sales and marketing initiatives underway to support Talicia's continued momentum. Our focus is on strengthening prescription growth while expanding number of patients helped by this treatment." The launch expands Cumberland's specialty product portfolio and reflects the company's strategy of leveraging its established commercial infrastructure to drive growth from its differentiated, FDA-approved brands. As part of the launch, Cumberland is utilizing its existing field sales force division with supporting marketing initiatives designed to increase awareness among gastroenterologists and other prescribing physicians. H. pylori infection affects approximately 35% of the U.S. adult population and is a leading cause of gastric cancer, contributing to an estimated 11,000 related deaths annually in the U.S. Cumberland and its commercialization partner are aligning key commercial resources to ensure broader access to this clinically differentiated therapy. About H. pylori H. pylori is a bacterial infection that affects approximately 35% of the U.S. adult population (an estimated 1.6 million U.S. patients are treated annually) rising to more than 50% globally. Classified by the World Health Organization (WHO) as a Group 1 carcinogen, H. pylori is the strongest known risk factor for gastric cancer (between 70% to 90% of cases with more than 27,000 Americans diagnosed with gastric cancer annually and approximately 800,000 deaths globally per year), a major risk factor for peptic ulcer disease (90% of cases) and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Eradication of H. pylori is becoming increasingly difficult, with current therapies failing in approximately 25-40% of patients who remain H. pylori-positive due to high resistance of H. pylori to antibiotics, especially clarithromycin, which is still commonly used in standard combination therapies. About Talicia® Approved by the FDA for the treatment of H. pylori infection in adults in November 2019, Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole). Talicia received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation and is also covered by U.S. patents extending patent protection through 2042 with additional patents and applications pending and granted in various territories worldwide. Talicia is also approved by the United Arab Emirates (UAE) Ministry of Health. For full prescribing information, visit . About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of pain and fever; Kristalose® (lactulose) oral, a prescription laxative, for the treatment of constipation; Sancuso® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Talicia® (omeprazole, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection. The company also has a series of Phase 2 clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis and Idiopathic Pulmonary Fibrosis, in addition to Duchenne muscular dystrophy. For more information on Cumberland's approved products, including full prescribing information, please visit the individual product websites, which can be found on the company's website at . Forward-Looking Statements This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the company's intent, belief or expectations, and can be identified by the use of terminology such as "may," "will," "expect," "believe," "intend," "plan," "estimate," "should," "seek," "anticipate," "look forward" and other comparable terms or the negative thereof. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's operation results. These factors include macroeconomic conditions, including rising interest rates and inflation, competition, an inability of manufacturers to produce Cumberland's products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the company's control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission ("SEC"), as well as the company's other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. SOURCE Cumberland Pharmaceuticals Inc. 21% more press release views with Request a Demo

上市批准临床2期引进/卖出合格传染病产品

2026-02-24

·PRNewswire

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

NASHVILLE, Tenn., Feb. 24, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its 2025 financial results and provide a company update after the market closes on Tuesday, March 3, 2026. A conference call will be held on March 3 at 4:30 p.m. Eastern Time to discuss the results and update. The link to register is . Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference. A replay of the call will be available for one year and can be accessed via the Investor Relations page of Cumberland's website or by visiting . Cumberland Pharmaceuticals is a specialty pharmaceutical company dedicated to providing unique products that improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of pain and fever; Kristalose® (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso® (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Talicia® (omeprazole, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection. The Company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis, the cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic Pulmonary Fibrosis. For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, found on the company's website at . SOURCE Cumberland Pharmaceuticals Inc. 21% more press release views with Request a Demo

临床2期上市批准财报

2026-02-07

·PRNewswire

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

Feb. 4, 2026 -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart disease in Duchenne muscular dystrophy (DMD) patients. The FDA's Fast Track program facilitates the development and expedites the review of a drug designed to treat a serious or life-threatening condition and unmet medical need. This designation provides an opportunity for more frequent communication with the FDA, enabling Cumberland, as the sponsor, to obtain early feedback and guidance. Under Fast Track, Cumberland can also submit portions of an application for marketing approval on a rolling basis. Cumberland requested Fast Track Designation to streamline the regulatory pathway for ifetroban for DMD heart disease. This Fast Track Designation follows the drug's receipt of both Orphan Drug Designation and Rare Pediatric Disease Designation, confirming both the urgency and the significant impact of the product for this indication. Cumberland previously announced positive results from its Phase 2 FIGHT DMD trial evaluating oral thromboxane receptor antagonist ifetroban in DMD heart disease, demonstrating a 5.4% improvement in left ventricular ejection fraction (LVEF) over 12 months of treatment. "The FDA's Fast Track Designation for ifetroban underscores the urgent and critical unmet medical need in DMD heart disease," said A.J. Kazimi, Cumberland founder and CEO. "This designation, combined with our breakthrough Phase 2 results, positions us to work closely with the FDA through more frequent interactions and expedited review processes to advance this promising heart-targeted therapy for DMD patients as efficiently as possible. We look forward to engaging with the Agency and our patient advocacy partners to bring this much-needed therapy to DMD patients and their families." DMD is a rare and incurable pediatric disease affecting approximately 1 in 3,500-5,000 male births caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart. Patients with DMD slowly lose muscle function, resulting in the inability to walk, difficulty breathing, and heart failure. While current treatments can help manage some DMD symptoms, there are no approved therapies specifically targeting DMD-related heart disease, highlighting a critical unmet medical need. Heart disease is the leading cause of death in DMD patients, with heart damage beginning early and progressing at different rates for each patient. Despite this, no treatments are currently approved specifically for DMD heart disease. The current treatment options include the use of corticosteroids to reduce inflammation and traditional heart disease medications to manage blood pressure and heart rate, reducing strain on the heart. While these therapies slow the onset and progression of DMD heart disease, none of them provides a lasting benefit for this unique form of heart disease or improves patient survival. Additionally, exon-skipping and gene therapies approved for DMD have shown no cardiac benefit to date. Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of pain and fever; Kristalose® (lactulose) oral, a prescription laxative, for the treatment of constipation; Sancuso® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Talicia® (omeprazole, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection. The company also has a series of Phase 2 clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis and Idiopathic Pulmonary Fibrosis, in addition to Duchenne muscular dystrophy. The content above comes from the network. if any infringement, please contact us to modify.

快速通道临床结果孤儿药

100 项与盐酸考尼伐坦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01236	盐酸考尼伐坦	C03XA02	DB00872

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心脏衰竭	美国	Cumberland Pharmaceuticals, Inc.	2005-12-29
低钠血症	美国	Cumberland Pharmaceuticals, Inc.	2005-12-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性失代偿性心力衰竭	临床3期	印度	Cumberland Pharmaceuticals, Inc.	2009-04-01
慢性低钠血症	临床2期	中国	北京福瑞康正医药技术研究所	2018-08-28
慢性低钠血症	临床2期	中国	江苏万高药业股份有限公司	2018-08-28
水中毒	临床2期	中国	北京福瑞康正医药技术研究所	2018-08-28
水中毒	临床2期	中国	江苏万高药业股份有限公司	2018-08-28
慢性心力衰竭	临床2期	美国	Cumberland Pharmaceuticals, Inc.	2002-11-01
失代偿性慢性心力衰竭	临床2期	美国	Cumberland Pharmaceuticals, Inc.	2002-11-01
肾脏疾病	临床1期	美国	Cumberland Pharmaceuticals, Inc.	2009-04-01
慢性充血性心力衰竭	临床阶段不明	美国	Astellas Pharma, Inc.	2009-07-01
类鼻疽	临床前	印度	Indian Institute of Technology Kharagpur	2025-05-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03000283 (CTgov)	临床1期	脑出血 \| 脑卒中 \| 脑水肿	7	Conivaptan	積繭餘壓鑰觸網廠範簾 = 衊獵鑰鹽選窪淵鏇觸艱範憲鹹選網窪膚願顧艱 (鹽襯遞衊獵築網衊繭觸, 醖醖壓積艱簾積廠蓋齋 ~ 範遞觸鹹網鹽糧淵願積) 更多	-	2020-04-17
NCT01451411 (CTgov)	临床3期	低钠血症	4	Conivaptan hydrochloride (Conivaptan Hydrochloride)	餘觸範積鹹顧獵鑰遞膚(齋願鏇選鬱鏇糧膚鹹積) = 淵製築襯觸願壓顧憲獵願廠繭鹽構簾鑰膚齋蓋 (鹽鹽網鏇選鑰壓鏇壓願, 5.3) 更多	-	2016-03-01
				Placebo (Placebo)	餘觸範積鹹顧獵鑰遞膚(齋願鏇選鬱鏇糧膚鹹積) = 齋艱衊夢衊鹹繭鬱艱願願廠繭鹽構簾鑰膚齋蓋更多
NCT00843986 (CONVERT-H, CTgov)	临床3期	低钠血症 \| 急性失代偿性心力衰竭	9	placebo (Placebo)	網鏇鹹襯簾艱淵鹹夢顧(網遞構繭鹹糧壓觸膚膚) = 積憲鑰繭網壓鬱獵夢憲選壓鬱網選範衊願壓蓋 (憲範製簾夢餘膚範觸網, 壓憲齋鑰壓範壓夢簾淵 ~ 餘醖鹹網窪廠範襯膚蓋) 更多	-	2010-10-01
				conivaptan (Conivaptan)	網鏇鹹襯簾艱淵鹹夢顧(網遞構繭鹹糧壓觸膚膚) = 淵窪繭鏇齋鬱築鑰糧觸選壓鬱網選範衊願壓蓋 (憲範製簾夢餘膚範觸網, 顧繭齋鏇窪襯鬱襯齋觸 ~ 獵觸鏇遞淵鏇襯鬱選鹹) 更多
NCT00592475 (CTgov)	临床2期	-	20	conivaptan (Regimen 1 Conivaptan 12.5 mg)	獵簾製願衊鏇鑰糧顧膚(膚壓鏇鬱廠選壓齋淵衊) = 選製壓夢淵淵築網糧艱糧積獵製衊繭鑰網憲範 (願襯淵膚築網獵鏇選淵, 4.375) 更多	-	2010-09-28
				conivaptan (Regimen 2 Conivaptan 25 mg)	獵簾製願衊鏇鑰糧顧膚(膚壓鏇鬱廠選壓齋淵衊) = 範鏇壓觸艱夢膚網鏇齋糧積獵製衊繭鑰網憲範 (願襯淵膚築網獵鏇選淵, 4.750) 更多
NCT00435591 (CTgov)	临床4期	低钠血症	121	placebo+Conivaptan (Dose Regimen 1)	壓糧餘窪鹽鏇簾艱廠範 = 窪鏇願簾餘鑰夢鏇膚願醖艱選憲艱範廠憲憲餘 (製蓋餘選顧鏇蓋衊夢艱, 窪糧襯艱壓構鏇艱鹽齋 ~ 網齋醖廠觸獵遞鏇膚鹹) 更多	-	2010-05-26
				Conivaptan (Dose Regimen 2)	壓糧餘窪鹽鏇簾艱廠範 = 壓壓網構鬱鏇繭網獵顧醖艱選憲艱範廠憲憲餘 (製蓋餘選顧鏇蓋衊夢艱, 構網繭襯廠醖繭鏇觸窪 ~ 網築積積鹽壓夢衊網齋) 更多
NCT00478192 (CTgov)	临床3期	低钠血症	50	Conivaptan (Regimen 1 Conivaptan QD)	鏇夢獵蓋餘觸選淵衊願(糧膚遞醖鑰觸淵選壓獵) = 衊鬱構網網餘膚顧網觸醖簾襯窪製選憲鹹獵膚 (構獵窪鬱醖蓋繭積築膚, 4.017) 更多	-	2010-04-21
				Conivaptan (Regimen 2 Conivaptan BID)	鏇夢獵蓋餘觸選淵衊願(糧膚遞醖鑰觸淵選壓獵) = 衊鏇積糧膚憲糧積願壓醖簾襯窪製選憲鹹獵膚 (構獵窪鬱醖蓋繭積築膚, 3.581) 更多